文献速递血栓与止血

Rilzabrutinib(一种口服布鲁顿酪氨酸激酶抑制剂)在免疫性血小板减少症患者中的疗效与安全性:2期B部分研究

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
PubMed 文献 · Am J Hematol · 2025-01-22

LUNA2 B部分是一项多中心1/2期研究,纳入26例持续性或慢性免疫性血小板减少症成人患者,口服rilzabrutinib 400 mg每日两次共24周。9例(35%)达到主要终点,即末12周中至少8周血小板≥50×10^9/L且未用救援药物;治疗相关不良事件多为1级,无治疗相关≥2级出血/血栓事件/感染、严重不良事件或死亡。

要点

  • 26例经治ITP患者中9例(35%)达到主要终点,血小板反应可持续平均9.3周。
  • 治疗相关不良事件发生率62%,主要为1级腹泻(35%)、头痛(23%)和恶心(15%)。
  • 无治疗相关≥2级出血/血栓事件/感染、严重不良事件或死亡,疲劳和女性健康有临床意义改善。

核心结论

  • Rilzabrutinib在既往接受过治疗的ITP患者中继续显示持久的血小板反应和良好的安全性。

研究设计与样本

  • LUNA2 B部分为多中心1/2期研究(NCT03395210,EudraCT 2017-004012-19),纳入26例ITP持续时间≥3个月、血小板计数<30×10^9/L且至少一种ITP治疗失败的成人患者。
  • 口服rilzabrutinib 400 mg每日两次,给药24周,可选长期扩展(LTE)。
  • 主要终点为安全性和主要治疗末12周中至少8周血小板计数≥50×10^9/L且未使用救援药物。
  • 研究入组时间为2018年3月22日至2023年1月31日。

主要发现

  • 基线中位血小板计数13×10^9/L,ITP病程10.3年,既往接受过六种ITP治疗,46%患者接受过脾切除术。
  • 9例(35%)患者达到主要终点。
  • 血小板计数≥50×10^9/L或≥30×10^9/L且较基线倍增(未用救援治疗)平均持续9.3周。
  • 11例(42%)符合LTE条件的患者仍在进行中,LTE期间中位血小板计数>80×10^9/L。
  • 主要治疗期间3例(12%)患者接受救援药物,LTE期间无患者接受救援药物。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Current treatments for persistent or chronic immune thrombocytopenia (ITP) are limited by inadequate response, toxicity, and impaired quality of life. The Bruton tyrosine kinase inhibitor rilzabrutinib was evaluated to further characterize safety and durability of platelet response. LUNA2 Part B is a multicenter, phase 1/2 study in adults with ITP (≥ 3 months duration, platelet count < 30 × 109/L) who failed ≥ 1 ITP therapy (NCT03395210, EudraCT 2017-004012-19). Oral rilzabrutinib 400 mg bid was given over 24 weeks, with optional long-term extension (LTE). Primary endpoints were safety and platelet counts ≥ 50 × 109/L on ≥ 8 of the last 12 weeks of main treatment without rescue medication. From 22 March2018 to 31 January2023, 26 patients were enrolled. Patients had baseline median platelet count 13 × 109/L, ITP duration 10.3 years, and six prior ITP therapies (46% splenectomized). Nine (35%) patients achieved the primary endpoint. Platelet counts ≥ 50 × 109/L or ≥ 30 × 109/L and doubling from baseline without rescue therapy were sustained for a mean 9.3 weeks. 11 (42%) LTE-eligible patients were ongoing with median LTE platelet > 80 × 109/L. Three (12%) patients received rescue medication during main treatment, none in LTE. Clinically meaningful improvements were observed in fatigue and women's health. With a median treatment duration of 167 days (main treatment), 16 (62%) patients had ≥ 1 treatment-related adverse event (AE), mainly grade 1, including diarrhea (35%), headache (23%), and nausea (15%). There was no treatment-related grade ≥ 2 bleeding/thrombotic events/infections, serious AE, or death. Rilzabrutinib continues to demonstrate durable platelet responses with favorable safety profile in previously treated ITP patients. Trial Registration: NCT03395210, EudraCT 2017-004012-19.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Cooper N, Jansen AJG, Bird R, et al. Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study. Am J Hematol. 2025. PMID: 39844469. doi:10.1002/ajh.27539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。